Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0043-1775825
Salivary Trefoil Factor (TFF3) in Stage I–II Periodontitis: A Prospective Clinical Study
Funding None.![](https://www.thieme-connect.de/media/10.1055-s-00051518/202303/lookinside/thumbnails/10-1055-s-0043-1775825_2350331-1.jpg)
Abstract
Objective This article evaluates the salivary trefoil factor levels using enzyme-linked immunosorbent assay and clinical parameters in stage I to II periodontitis subjects.
Materials and Method A total of 44 subjects with periodontitis and healthy periodontium were enrolled for the study as per the inclusion criteria. The subjects were selected and categorized as group A (control group) and group B (test group). Scaling was performed on healthy subjects at baseline and 1 month if necessary and scaling and root planing was performed for periodontitis subjects. Trefoil factor 3 (TFF3) levels was analyzed at first and post-nonsurgical periodontal therapy followed by clinical parameters, respectively.
Statistical Analysis Inferential statistics were performed using independent t-test and repeated measures of analysis of variance (ANOVA) test. Independent t-test was used for the intergroup comparison of all the variables. Repeated measures of ANOVA test along with post hoc Bonferroni test was used for the intragroup comparison and the level of statistical significance was set at 0.001.
Results Difference in TFF3 levels and clinical parameters was seen between groups A and B, which was statistically significant.
Conclusion Within the constraints of the study, it can be stated that TFF3 is a relevant biomarker to determine the activity and association of periodontal and systemic diseases, gastrointestinal disorders, and inflammatory bowel diseases.
Publication History
Article published online:
06 November 2023
© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Taalab MR, Mahmoud SA, Moslemany RME, Abdelaziz DM. Intrapocket application of tea tree oil gel in the treatment of stage 2 periodontitis. BMC Oral Health 2021; 21 (01) 239
- 2 Keles Yucel ZP, Afacan B, Atmaca İlhan H, Kose T, Emingil G. The trefoil factor family 1 (TFF-1) and 3 (TFF-3) are upregulated in the saliva, gingival crevicular fluid and serum of periodontitis patients. Oral Dis 2022; 28 (04) 1240-1249
- 3 Vestergaard EM, Poulsen SS, Grønbaek H. et al. Development and evaluation of an ELISA for human trefoil factor 3. Clin Chem 2002; 48 (10) 1689-1695
- 4 Aihara E, Engevik KA, Montrose MH. Trefoil factor peptides and gastrointestinal function. Annu Rev Physiol 2017; 79: 357-380
- 5 Houben T, Harder S, Schlüter H, Kalbacher H, Hoffmann W. Different forms of TFF3 in the human saliva: heterodimerization with IgG Fc binding protein (FCGBP). Int J Mol Sci 2019; 20 (20) 5000-5016
- 6 Haririan H, Andrukhov O, Laky M. et al. Saliva as a source of biomarkers for periodontitis and periimplantitis. Front Dent Med 2021; 2: 687638-687646
- 7 Papapanou PN, Sanz M, Buduneli N. et al. Periodontitis: consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Periodontol 2018; 89 (Suppl. 01) S173-S182
- 8 Lobene RR, Weatherford T, Ross NM, Lamm RA, Menaker L. A modified gingival index for use in clinical trials. Clin Prev Dent 1986; 8 (01) 3-6
- 9 Turesky S, Gilmore ND, Glickman I. Reduced plaque formation by the chloromethyl analogue of vitamin C. J Periodontol 1970; 41 (01) 41-43
- 10 Mühlemann HR, Son S. Gingival sulcus bleeding–a leading symptom in initial gingivitis. Helv Odontol Acta 1971; 15 (02) 107-113
- 11 Meesala D, Penmetsa GS, Dwarakanath CD, Manyam R. Effect of initial periodontal therapy on salivary trefoil factor (TFF3) in otherwise healthy subjects with gingivitis and chronic periodontitis. Contemp Clin Dent 2018; 9 (Suppl. 01) S11-S16
- 12 Engvall E. The ELISA, enzyme-linked immunosorbent assay. Clin Chem 2010; 56 (02) 319-320
- 13 Caton JG, Armitage G, Berglundh T. et al. A new classification scheme for periodontal and peri-implant diseases and conditions - introduction and key changes from the 1999 classification. J Periodontol 2018; 89 (Suppl. 01) S1-S8
- 14 Palwankar P, Rana M, Arora K, Deepthy C. Evaluation of non-surgical therapy on glutathione levels in chronic periodontitis. Eur J Dent 2015; 9 (03) 415-422
- 15 Pranam S, Palwankar P, Pandey R, Goyal A. Evaluation of efficacy of coenzyme Q10 as an adjunct to nonsurgical periodontal therapy and its effect on crevicular superoxide dismutase in patients with chronic periodontitis. Eur J Dent 2020; 14 (04) 551-557
- 16 Palwankar P, Jain S, Pandey R, Mahesh S. IgA levels among Type 2 diabetic and non-diabetic patients with periodontitis: a prospective clinical study. Eur J Dent 2023; 17 (03) 823-827
- 17 Chapple ILC, Mealey BL, Van Dyke TE. et al. Periodontal health and gingival diseases and conditions on an intact and a reduced periodontium: consensus report of workgroup 1 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Periodontol 2018; 89 (Suppl. 01) S74-S84
- 18 Choi YM, Lee JY, Choi J, Joo JY. Effect of root planing on the reduction of probing depth and the gain of clinical attachment depending on the mode of interproximal bone resorption. J Periodontal Implant Sci 2015; 45 (05) 184-189